Date: 17 November 2026
Regulatory Compliance Update
The inspection was conducted at the InvaGen manufacturing facility located in Hauppauge, Long Island, New York, USA from 19 October 2026 to 22 October 2026.
Via communication dated 17 November 2026, the USFDA has classified this inspection as No Action Indicated (NAI).
This communication follows the company's previous intimation regarding the inspection dated 23 October 2026.
KMP / Board / Auditor Changes
Not Specified
Dividend Declaration or Non-Declaration
Not Specified
Board Meeting Outcomes
Not Specified
Financial Results
Not Specified
Disinvestment / Strategic Actions
Not Specified
Other Operational / Legal / Strategic Disclosures
The disclosure confirms regulatory compliance status for the US manufacturing operations of InvaGen Pharmaceuticals Inc., a wholly owned subsidiary.